We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.36B
1-Year Est. Return 204.53%
This Fund
S&P 500
This Quarter Est. Return
+16.5%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$2.25B
AUM Growth
+$394M
Cap. Flow
+$407M
Cap. Flow %
18.04%
Top 10 Hldgs %
64.72%
Holding
86
New
21
Increased
10
Reduced
4
Closed
15

Top Buys

Rank Stock Value
1
NUVB icon
Nuvation Bio
NUVB
+$148M
2
ANAB icon
AnaptysBio
ANAB
+$99.1M
3
KURA icon
Kura Oncology
KURA
+$60.7M
4
EWTX icon
Edgewise Therapeutics
EWTX
+$39.7M
5
DSGN icon
Design Therapeutics
DSGN
+$38.4M

Top Sells

Rank Stock Value
1
AMTI
Applied Molecular Transport Inc. Common Stock
AMTI
+$44.3M
2
GERN icon
Geron
GERN
+$30.1M
3
VINC
Vincerx Pharma, Inc. Common Stock
VINC
+$10M
4
ACRS icon
Aclaris Therapeutics
ACRS
+$9.77M
5
CMAX
CareMax, Inc. Class A Common Stock
CMAX
+$7.51M

Sector Composition

Rank Sector Weight
1 Healthcare 98.25%
2 Financials 0.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BLSA
51
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$2.11M 0.09%
200,000
– –
MLTX icon
52
MoonLake Immunotherapeutics
MLTX
$1.59B
$2.04M 0.09%
200,000
– –
FLACU
53
DELISTED
Frazier Lifesciences Acquisition Corporation Unit
FLACU
$2.03M 0.09%
200,000
– –
FVAM
54
DELISTED
5:01 Acquisition Corp
FVAM
$2M 0.09%
200,000
– –
EUCR
55
DELISTED
Eucrates Biomedical Acquisition Corp. Ordinary Shares
EUCR
$2M 0.09%
+200,000
New +$2.05M
CHFW.U
56
DELISTED
Consonance-HFW Acquisition Corp. Units, each consisting of one Class A Ordinary Share, and one-third
CHFW.U
$1.95M 0.09%
200,000
– –
CDAK
57
DELISTED
Codiak BioSciences, Inc. Common Stock
CDAK
$1.74M 0.08%
115,195
– –
PMVP icon
58
PMV Pharmaceuticals
PMVP
$58.7M
$1.65M 0.07%
50,000
– –
ARYD
59
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
$1.57M 0.07%
+150,000
New +$1.62M
RPTX
60
DELISTED
Repare Therapeutics
RPTX
$1.53M 0.07%
50,000
– –
PRDS
61
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$1.49M 0.07%
+150,000
New +$1.55M
MGTX icon
62
MeiraGTx Holdings
MGTX
$1.09B
$1.37M 0.06%
94,819
– –
CMAXW
63
DELISTED
CareMax, Inc. Warrant
CMAXW
$1.21M 0.05%
100,000
– –
TMPM
64
DELISTED
Turmeric Acquisition Corp. Class A Ordinary Shares
TMPM
$977K 0.04%
+100,000
New +$1.02M
KNTE
65
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$779K 0.03%
25,000
– –
EUCRW
66
DELISTED
Eucrates Biomedical Acquisition Corp. Warrant
EUCRW
$665K 0.03%
+66,666
New +$108K
SNCE
67
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$573K 0.03%
2,825
-7,175
-72% -$1.56M
FSTX
68
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$498K 0.02%
+46,000
New +$447K
OMEG
69
DELISTED
Omega Alpha SPAC Class A Ordinary Shares
OMEG
$495K 0.02%
+50,000
New +$519K
MTCR
70
DELISTED
Metacrine, Inc. Common Stock
MTCR
$386K 0.02%
62,207
-271,125
-81% -$2.4M
TMPMW
71
DELISTED
Turmeric Acquisition Corp. Warrant
TMPMW
$326K 0.01%
+33,333
New +$53.9K
ACRS icon
72
Aclaris Therapeutics
ACRS
$744M
– –
-1,509,812
Closed -$9.77M
ASMB icon
73
CALL
Assembly Biosciences
ASMB
$507M
– –
-1,483
Closed -$108K
BIIB icon
74
CALL
Biogen
BIIB
$30.4B
– –
-254,100
Closed -$62.2M
GERN icon
75
Geron
GERN
$930M
– –
-18,939,925
Closed -$30.1M
1 2
3
4

Similar funds

HFM
Harvest Fund Management Beijing, China $2.35B AUM 49.85% 1-Year Est. Return
CC
Capital Counsel New York $2.35B AUM 21.34% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
ROIC
Route One Investment Company San Francisco, California $2.35B AUM 11.7% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
G
GenTrust Miami, Florida $2.34B AUM 18.43% 1-Year Est. Return
MC
Moors & Cabot Boston, Massachusetts $2.34B AUM 30.42% 1-Year Est. Return
CIP
Cornerstone Investment Partners Atlanta, Georgia $2.38B AUM 32.49% 1-Year Est. Return

EcoR1 Capital's Q1 2021 Portfolio in Review

As of Q1 2021, EcoR1 Capital held 86 positions worth $2.25B, up 21% from $1.86B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

EcoR1 Capital deployed $407M of net new capital in Q1 2021, opening 21 new positions and adding to 10 existing holdings. Its largest new stake was Nuvation Bio: 13,247,017 shares worth $138M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 94% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Applied Molecular Transport Inc. Common Stock, an estimated $44.3M trimmed.

  • EcoR1 Capital's largest Q1 2021 buy was Nuvation Bio: 13,247,017 shares worth $138M.
  • EcoR1 Capital added most to AnaptysBio in Q1 2021, an estimated $99.1M increase.
  • EcoR1 Capital's biggest Q1 2021 reduction was Applied Molecular Transport Inc. Common Stock, cutting an estimated $44.3M.
  • EcoR1 Capital fully exited Geron in Q1 2021, selling an estimated $30.1M.
  • EcoR1 Capital's ten largest holdings make up 65% of its $2.25B portfolio in Q1 2021.
  • EcoR1 Capital opened 21 new positions and closed 15 in Q1 2021.
  • EcoR1 Capital's portfolio value rose 21% quarter-over-quarter to $2.25B.

Based on EcoR1 Capital's 13F filing for Q1 2021, filed 17 May 2021.